Cancer biology in diabetes update: Focusing on antidiabetic drugs

Emi Kawakita,Keizo Kanasaki
DOI: https://doi.org/10.1111/jdi.14152
2024-03-10
Journal of Diabetes Investigation
Abstract:The long‐term influence of antidiabetic drugs use on cancer biology is not fully elucidated. We summarize and discuss the potential influence of each diabetes therapy in cancer 'initiation', 'promotion' and 'progression'. The association of type 2 diabetes with certain cancer risk has been of great interest for years. However, the effect of diabetic medications on cancer development is not fully understood. Prospective clinical trials have not elucidated the long‐term influence of hypoglycemic drugs on cancer incidence and the safety for cancer‐bearing patients with diabetes, whereas numerous preclinical studies have shown that antidiabetic drugs could have an impact on carcinogenesis processes beyond the glycemic control effect. Because there is no evidence of the safety profile of antidiabetic agents on cancer biology, careful consideration would be required when prescribing any medicines to patients with diabetes and existing tumor. In this review, we discuss the potential influence of each diabetes therapy in cancer 'initiation', 'promotion' and 'progression'.
endocrinology & metabolism
What problem does this paper attempt to address?